Literature DB >> 180844

Clinical and serologic responses of volunteers infected with phlebotomus fever virus (Sicilian type).

P J Bartelloni, R B Tesh.   

Abstract

Twenty volunteers were inoculated with various doses of human serum containing Phlebotomus fever virus (Sicilian type) to determine their clinical and serologic responses as well as the human infectious dose50 of the virus. All infected subjects developed fever which varied in duration from 6 to 74 hours. The most common symptoms during sandfly fever were headache, anorexia, myalgia, photophobia, low back and retro-orbital pain. Infected individuals developed a marked leukopenia characterized by an initial lymphopenia followed by protracted neutropenia. Little complement fixing antibody was detected in convalescent sera but most subjects developed significant rises in hemagglutination inhibiting antibodies. All infected subjects developed specific neutralizing antibodies with titers ranging from 1:40 to 1:2,560. Of the three serologic tests performed, the plaque reduction neutralization method appears to be the most sensitive test for detecting antibodies to Phlebotomus fever viruses.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 180844     DOI: 10.4269/ajtmh.1976.25.456

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  Characterization of the Punta Toro species complex (genus Phlebovirus, family Bunyaviridae).

Authors:  Gustavo Palacios; Michael R Wiley; Amelia P A Travassos da Rosa; Hilda Guzman; Evelia Quiroz; Nazir Savji; Jean-Paul Carrera; Ana Valeria Bussetti; Jason T Ladner; W Ian Lipkin; Robert B Tesh
Journal:  J Gen Virol       Date:  2015-05-01       Impact factor: 3.891

Review 2.  Emergence of Toscana virus in the mediterranean area.

Authors:  Remi N Charrel; Laurence Bichaud; Xavier de Lamballerie
Journal:  World J Virol       Date:  2012-10-12

3.  The S segment of Punta Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in the Syrian hamster and codes for a type I interferon antagonist.

Authors:  Lucy A Perrone; Krishna Narayanan; Melissa Worthy; C J Peters
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

4.  B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans.

Authors:  Zhannat Z Nurgalieva; Margaret E Conner; Antone R Opekun; Carl Q Zheng; Susan N Elliott; Peter B Ernst; Michael Osato; Mary K Estes; David Y Graham
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 5.  [Sandfly fever-a "neglected" disease].

Authors:  B Stahn; H Sudeck; H Frickmann; A Krüger; H G Burchard; D Wiemer
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

6.  Laboratory diagnosis of Toscana virus infection by enzyme immunoassay with recombinant viral nucleoprotein.

Authors:  D Soldateschi; G M dal Maso; M Valassina; L Santini; S Bianchi; M G Cusi
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  Detection of human immunoglobulins G and M antibodies to Rift Valley fever virus by enzyme-linked immunosorbent assay.

Authors:  B Niklasson; C J Peters; M Grandien; O Wood
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

8.  Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

Authors:  J J Kirsi; J A North; P A McKernan; B K Murray; P G Canonico; J W Huggins; P C Srivastava; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

9.  Challenge model for Helicobacter pylori infection in human volunteers.

Authors:  D Y Graham; A R Opekun; M S Osato; H M T El-Zimaity; C K Lee; Y Yamaoka; W A Qureshi; M Cadoz; T P Monath
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

10.  Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model.

Authors:  Robert B Tesh; Juan Arroyo; Amelia P A Travassos Da Rosa; Hilda Guzman; Shu-Yuan Xiao; Thomas P Monath
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.